Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
Devonian plans a dual listing, adding NYSE American trading while keeping its TSX Venture presence.
Rhea-AI Summary
Devonian Health Group (DHGR, DVHGF) expects its common shares and warrants from an underwritten public offering to begin trading on the NYSE American as early as September 16, 2026, under the symbols “DHGR” and “DHGR WS”.
The listing and start of trading are subject to market conditions, final NYSE American authorization of the company’s listing application, and continued compliance with exchange rules. Devonian will remain listed on the TSX Venture Exchange, where it has reserved the symbol “DHGR” and plans to request a change of its current symbol from “GSD” to “DHGR” at a later date.
Positive
- Planned NYSE American listing of common shares and warrants under symbols DHGR and DHGR WS
- Targeted NYSE American trading start as early as September 16, 2026
- Company to maintain existing TSX Venture Exchange listing while expanding to U.S. market
- Reserved DHGR symbol on TSXV with intention to align ticker across exchanges
Negative
- NYSE American listing and trading start are conditional on final exchange authorization
- Listing is also subject to market conditions and ongoing rule compliance, creating execution uncertainty
Key Figures
- Expected NYSE American trading date
- September 16, 2026
- Common shares and warrants, subject to final exchange authorization and market conditions
Key Terms
underwritten public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Devonian
Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.
Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the-art extraction facility. Devonian is traded publicly on the TSXV (TSXV: GSD) and currently quoted on the OTCQB Venture Market (OTCQB: DVHGF).
For more information, visit www.groupedevonian.com.
Forward-looking statements
All statements, other than statements of historical fact contained in this press release, including but not limited to those relating to the anticipated listing on the NYSE American and concurrent underwritten public offering and the proposed NYSE American and proposed change to the TSXV ticker symbols, and, generally, the statements contained under the "About Devonian" section, constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable securities laws (collectively, "forward-looking statements"). These forward-looking statements are based on the Company's current expectations, estimates and assumptions as of the date of this press release. Such forward-looking statements may be identified by the use of words such as "anticipates," "believes," "expects," "intends," "plans," "may," "could," "would," "should," "will," or similar expressions, including negative or grammatical variations thereof, indicating that certain actions, events or results may, could or will occur or be achieved.
By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in the Company's other filings with the applicable securities regulators of Canada and in the "Risk Factors" section in the prospectus related to the Offering filed with the SEC. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/devonian-health-group-inc-anticipates-to-commence-trading-on-the-nyse-american-302876638.html
SOURCE Devonian Health Group Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What symbols will Devonian use on the NYSE American if the listing is completed?
Devonian expects its common shares to trade on the NYSE American under the symbol “DHGR” and its warrants under the symbol “DHGR WS”, subject to final authorization by the exchange and market conditions.
When does Devonian expect NYSE American trading to begin?
The company anticipates that trading of its common shares and warrants on the NYSE American could commence as early as September 16, 2026, assuming all conditions are satisfied.
Will Devonian Health Group remain listed on the TSX Venture Exchange?
Yes. The company will remain listed on the TSX Venture Exchange and has reserved the symbol “DHGR” there. It intends to request a change of its current TSXV trading symbol from “GSD” to “DHGR” at a later date.
What conditions must be met before Devonian’s securities trade on the NYSE American?
The planned NYSE American listing and trading are subject to market conditions, final authorization by the NYSE American of Devonian’s listing application, and the company’s continued compliance with the exchange’s rules.